Flyer

Archivos de Medicina

  • ISSN: 1698-9465
  • Journal h-index: 27
  • Journal CiteScore: 11.20
  • Journal Impact Factor: 8.24
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
+44 7460731551
Awards Nomination
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Electronic Journals Library
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Proquest Summons
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Google Scholar
  • SHERPA ROMEO
  • Secret Search Engine Labs
Share This Page

Abstract

Infección por SARS-CoV-2 en Dos Pacientes en Tratamiento con Adalimumab

Lavieri AJ, Greco CF and Raco SC

With the onset of the SARS-CoV-2 pandemic, there is uncertainty about whether biological agents may place patients at increased risk of infection or a more severe disease course, either from COVID-19 or its underlying pathology. This commentary offers patient advice recommendations based on the current available evidence. Although there are currently no specific data on infected patients being treated with biologics, we present two cases, which provide information on this situation. We conclude that biological agents would not have a negative effect on this population, in the face of possible viral infection.